Sasaki Masato, Sudoh Toshiaki, Fujimura Akio
Department of Pharmacology, Jichi Medical School, Tochigi, Japan.
Am J Ther. 2005 May-Jun;12(3):223-5.
This study was undertaken to examine whether the pharmacokinetic profiles of ranitidine and nizatidine, the H2 antagonists, differed with repeated doses in very elderly patients (>80 years old). Ranitidine (150 mg) or nizatidine (150 mg) was given twice daily in 10 very elderly female patients for 14 days. This study was a randomized, crossover design with a wash-out period of 14 days. Pharmacokinetic profiles were determined after first (on day 1) and 27th (on day 14) doses of each agent. The maximum plasma drug concentration (Cmax) and area under the plasma drug concentration-time curve (AUC) were significantly greater after the 27th than after the first dose in the ranitidine but not in the nizatidine trials. The accumulation of ranitidine in plasma tended to be greater than that of nizatidine. These results suggest that nizatidine is safer for the repeated treatment in very elderly patients.
本研究旨在探讨H2拮抗剂雷尼替丁和尼扎替丁在极高龄患者(>80岁)中重复给药时的药代动力学特征是否存在差异。10名极高龄女性患者每日两次服用雷尼替丁(150毫克)或尼扎替丁(150毫克),共14天。本研究采用随机交叉设计,洗脱期为14天。在每种药物的首次(第1天)和第27次(第14天)给药后测定药代动力学特征。在雷尼替丁试验中,第27次给药后的最大血浆药物浓度(Cmax)和血浆药物浓度-时间曲线下面积(AUC)显著高于首次给药后,但在尼扎替丁试验中并非如此。雷尼替丁在血浆中的蓄积倾向大于尼扎替丁。这些结果表明,尼扎替丁在极高龄患者重复治疗中更安全。